公卫人

 找回密码
 立即注册

QQ登录

只需一步,快速开始

查看: 4441|回复: 6
打印 上一主题 下一主题

[分享] Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA

[复制链接]
跳转到指定楼层
1#
sampson2010 发表于 2015-1-29 11:29:04 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式

注册后推荐绑定QQ,之后方才可以使用下方的“用QQ帐号登录”。

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
本帖最后由 sampson2010 于 2015-1-29 11:33 编辑
% ~2 B7 l" f) q! ]7 D$ q3 w( i% v, a! t+ z5 v

, P* m。 @/ P4 u0 z
& ^$ V) L+ W/ B/ E: q6 ]Title: Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines: k' z8 `1 ]/ w" e( t: Z  J
Author(s): Tom Brody PhD University of California at Berkeley  ^. ^% ?" j9 S- W. A/ C2 j8 i
Publisher: Academic Press       
3 d; `5 W: }- }Year: 2011
+ o$ V4 J$ }1 X6 E- |8 LEdition: 1
) u; |0 [; y" A' OLanguage: English       
8 Z' x+ r! T3 oPages: 638
& p) H1 W( y+ S。 o" z2 MSize: 7 MB (7293100 bytes)       
3 z1 N4 u, U) u1 nExtension: pdf

# B+ S6 `/ F" D8 r' ^' p
2 q$ U0 U6 T8 l1 NClinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, consent forms and package inserts. It provides extensive information on both US and international regulatory guidelines and features concrete examples of study design from the medical literature. This book is intended to orient those new to clinical trial design and provide them with a better understanding of how to conduct clinical trials. It will also act as a guide for the more experienced by detailing endpoint selection and illustrating how to avoid unnecessary pitfalls. This book is a straightforward and valuable reference for all those involved in clinical trial design. ) O; j  w3 G) ?
Provides extensive coverage of the "study schema" and related features of study designOffers a "hands-on" reference that contains an overview of the process, but more importantly details a step-by-step account of clinical trial designFeatures examples from the medical literature to highlight how investigators choose the most suitable endpoint(s) for clinical trial and includes graphs from real clinical trials to help explain each concept in study designIntegrates clinical trial design, pharmacology, biochemistry, cell biology and legal aspects to provide readers with a comprehensive look at all aspects of clinical trialsIncludes chapters on core material and important ancillary topics, such as package inserts, consent forms, and safety reporting forms used in the United States, England and Europe
" A9 W- C  ^, C6 w+ U+ g1 u* UFor complimentary access to our sample chapter (chapter 24), please copy and paste this link into your browser:
9 z' [( q$ t# t% j0 I7 [; F; c* Y' x' Q" g5 U
Table of contents : 5 T# ~9 Q; A  W. M
Content:
2 N: S. i' M3 m' V# VFront-matter, Pages i,iii9 E  t; K9 x6 H/ A1 y* m
Copyright, Page iv
) C& J5 ?1 l; sDedication, Page v( {) {9 @! i; E$ H8 X
Acknowledgments, Pages xv-xvi0 s+ n1 e) e7 \
Preface, Pages xvii-xxi  w2 }  D2 @' u0 l2 ~& F" \
Introduction, Pages xxiii-xxv
2 p. \* |/ d, EAbbreviations and Definitions, Pages xxvii-xxxi
( F6 P2 U; a8 B; D0 C( TBiography, Page xxxiii9 [9 B+ J- R6 L( i; s
Chapter 1 - The Origins of Drugs, Pages 1-15
! N8 ~- u9 Q& [. ]5 O+ J+ K$ mChapter 2 - Introduction to Regulated Clinical Trials, Pages 17-50, M  d* n$ [) ]& t
Chapter 3 - Run-in Period, Pages 51-618 ?& x* l) g: Q7 h0 D
Chapter 4 - Inclusion/Exclusion Criteria, Stratification, and Subgroups – Part I, Pages 63-89
; a! \& g; }; ?Chapter 5 - Inclusion and Stratification Criteria – Part II, Pages 91-110
4 Q( {5 p9 M! E: R% l9 B" `Chapter 6 - Randomization, Allocation, and Blinding, Pages 111-129
3 ~$ |1 J: Q9 n4 V3 t1 P1 kChapter 7 - Placebo Arm as Part of Clinical Study Design, Pages 131-141
/ }& C# S0 `: R' {* ]8 b3 |7 ZChapter 8 - Intent to Treat Analysis vs. Per Protocol Analysis, Pages 143-164
+ \! C; L  R+ v. c4 H2 AChapter 9 - Biostatistics, Pages 165-190* o0 g- v8 u' O! \/ u
Chapter 10 - Introduction to Endpoints for Clinical Trials in Pharmacology, Pages 191-195
- u. q7 H( M/ n9 [1 a- N! {: EChapter 11 - Endpoints in Clinical Trials on Solid Tumors – Objective Response, Pages 197-211' {5 b/ Y# Y' t8 ^+ w
Chapter 12 - Oncology Endpoints: Overall Survival and Progression-free Survival, Pages 213-236% W" \+ z" H( }2 G/ S
Chapter 13 - Oncology Endpoints: Time to Progression, Pages 237-250
; a* e2 ]% k+ n  lChapter 14 - Oncology Endpoint: Disease-Free Survival, Pages 251-261
1 ?# V2 D+ I' z3 l& \Chapter 15 - Oncology Endpoint: Time to Distant Metastasis, Pages 263-270
* n* D3 y2 d+ d( ~4 NChapter 16 - Neoadjuvant Therapy versus Adjuvant Therapy, Pages 271-277
9 J; F. l7 M+ y7 N* ZChapter 17 - Hematological Cancers, Pages 279-325! G0 x+ Y' `) I: n+ s* O# v
Chapter 18 - Biomarkers and Personalized Medicine, Pages 327-353# h9 l5 Y. n- v( x& f! O
Chapter 19 - Endpoints in Immune Diseases, Pages 355-367
" N& A3 G: e9 R) C6 o6 {8 gChapter 20 - Endpoints in Clinical Trials on Infections, Pages 369-382: {! W: L( Z. }6 V' V
Chapter 21 - Health-Related Quality of Life, Pages 383-400
/ Z( m& ~; Y. U# j. j  N' {8 U6 YChapter 22 - Health-Related Quality of Life Instruments for Immune Disorders, Pages 401-4109 y7 ~% F) O, }4 V6 m8 r
Chapter 23 - Health-Related Quality of Life Instruments and Infections, Pages 411-414
+ L* ~- i4 h( v' ]Chapter 24 - Drug Safety, Pages 415-469
# I; l+ N: |' O8 T$ |。 t, ^Chapter 25 - Mechanism of Action, Part I, Pages 471-491
$ d5 i: g# P# U2 cChapter 26 - Mechanisms of Action, Part II – Cancer, Pages 493-5010 G5 H) y% ?" b+ M: S/ {: k
Chapter 27 - Mechanisms of Action, Part III – Immune Disorders, Pages 503-515
. |( E! m0 H$ o4 }9 C) d) SChapter 28 - Mechanisms of Action, Part IV – Infections, Pages 517-533& Z2 O* m9 J" e& R" l1 T
Chapter 29 - Consent Forms, Pages 535-5593 g( l; c& {6 N0 {. T) N% d; _& Z9 A1 j
Chapter 30 - Package Inserts, Pages 561-575
。 {4 R+ W4 A/ j; K# ZChapter 31 - Regulatory Approval, Pages 577-6053 m/ ]5 ~! t3 v. S, s
Chapter 32 - Patents, Pages 607-623
1 U, {4 M6 f8 v6 f  u  J$ w. Y; pIndex, Pages 625-638
# i) V. I0 Y" o. z4 `3 M7 W2 u' s
6 h4 r3 r, U3 i4 e Clinical Trials Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and.pdf (6.96 MB, 下载次数: 176)
. R3 v8 J8 g/ b  t+ v! w1 L3 M& e" X& a" |+ Z
来自群组: RGCE

评分

参与人数 1钢镚 +20 收起 理由
hoozoo + 20 积极发布原创帖子内容,再接再厉!

查看全部评分

本帖被以下淘专辑推荐:

2#
biostat 发表于 2015-3-3 09:20:10 | 只看该作者
赞一个!
3#
AprilChen0424 发表于 2016-11-6 17:36:05 | 只看该作者
谢谢,这本guideline吧信息整合得很全,值得一读
4#
ghgzw 发表于 2016-11-12 19:39:36 | 只看该作者
谢谢,可惜是第一版的。
5#
ling820927 发表于 2017-3-1 14:29:31 | 只看该作者
怎么下载不来
6#
liuql10 发表于 2017-6-4 16:29:39 | 只看该作者
哇,太棒的书!谢谢楼主分享
7#
cxfsoccer 发表于 2019-12-9 16:14:44 | 只看该作者
先仔细读读再说。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

充值|至尊会员||公卫人 ( )

GMT+8, 2020-2-11 01:45 , Processed in 0.126367 second(s), 36 queries , Gzip On.

Powered by X3.4

Copyright © 2001-2020, Tencent Cloud.

快速回复 返回顶部 返回列表
福星彩票计划群 博发彩票计划群 山东11选5计划 上海11选5 吉林快3代理 千禧彩票计划群 极速赛车彩票软件 秒速赛车登陆 北京两步彩走势图 千禧彩票登陆